Table 1 Characteristics of included GWAS data
From: Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis
Trait | Consortium | Sample size | Population | Journal | Year |
|---|---|---|---|---|---|
Druggable Genes | / | 4479 genes | European | Science Translational Medicine | 2017 |
eQTL | Â | Â | Â | Â | Â |
 Blood | eQTLGen | 31,684 individuals | European | Nature Genetics | 2021 |
pQTL | Â | Â | Â | Â | Â |
 Plasma proteome  Plasma proteome  Plasma proteome | deCODE / Pharma Proteomics | 4,907 proteins 1,699 proteins 2,923 proteins | European European European | Nature Genetics Nature Genetics Nature | 2021 2020 2023 |
Disease | Â | Â | Â | Â | Â |
 Myasthenia Gravis (MG)  Early-onset MG  Late-onset MG | IMGGC IMGGC IMGGC | 38,243 (1873 cases, 36,370 controls) 3,313 (595 cases, 2,718 controls) 34,930 (1,278 cases, 33,652 controls) | European European European | PNAS PNAS PNAS | 2022 2022 2022 |